Madiha Sajjad, MD
Hospitalist · Mesa, AZNPI 1902103138
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 174 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 18.2% — the pattern of someone who eats at a lot of different presentations. Among hospitalist clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 174 payments — averaging $17.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$564
- Amgen$361
- Lilly USA, LLC$286
- Averitas Pharma Inc.$197
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$185
- Novartis$184
- plus $1K from 29 others
What the payments were for
- Food & beverage$3,092100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 23 | $564 |
| Amgen(2 entities) | 25 | $361 |
| Lilly USA, LLC | 25 | $286 |
| Averitas Pharma Inc. | 8 | $197 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 12 | $185 |
| Novartis | 9 | $184 |
| Boehringer Ingelheim | 10 | $157 |
| GSK | 8 | $140 |
| Novo Nordisk | 8 | $135 |
| Abbott | 5 | $115 |
| Kowa Pharmaceuticals America, Inc. | 5 | $85 |
| Bardy Diagnostics, Inc. | 4 | $77 |
| Teva Pharmaceuticals USA, Inc. | 2 | $51 |
| Philips North America LLC | 3 | $46 |
| AbbVie | 2 | $45 |
| Merck | 2 | $43 |
| Medicure Pharma Inc. | 1 | $40 |
| Seqirus USA Inc | 2 | $34 |
| Johnson & Johnson | 2 | $33 |
| Topcon Healthcare Solutions, Inc. | 1 | $30 |
| Bayer | 2 | $29 |
| Sanofi-aventis U.S. LLC | 2 | $28 |
| Sumitomo Pharma America, Inc. | 1 | $26 |
| Globus Medical | 1 | $25 |
| Nevro Corp. | 1 | $25 |
| Pfizer | 1 | $22 |
| Intra-sana Laboratories | 1 | $21 |
| Impulse Dynamics (USA) Inc. | 1 | $19 |
| Vivus LLC | 1 | $17 |
| Ultragenyx Pharmaceutical Inc. | 1 | $16 |
| Exact Sciences | 1 | $15 |
| Boston Scientific | 1 | $15 |
| Dexcom, Inc. | 1 | $14 |
| Almatica Pharma LLC | 1 | $12 |
| Zyla Life Sciences, Inc. | 1 | $11 |
How this compares
$3,104 in reported general payments places this provider in the 95th percentile of 578 hospitalist providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 113 | $171,389 |
| JardianceEmpagliflozin | 62 | $90,557 |
| MounjaroTirzepatide | 51 | $82,495 |
| EliquisApixaban | 58 | $78,493 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 29 | $37,121 |
| TrulicityDulaglutide | 13 | $30,541 |
| Tresiba Flextouch U-100Insulin Degludec | 30 | $29,032 |
| XareltoRivaroxaban | 14 | $24,230 |
| ProliaDenosumab | 11 | $18,575 |
| Repatha SureclickEvolocumab | 17 | $16,421 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 14 | $12,640 |
| Spiriva RespimatTiotropium Bromide | 12 | $8,762 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 21 | $6,928 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 29 | $5,648 |
| Pitavastatin Calcium | 14 | $4,834 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $135 | $171,389113 claims |
| Lilly USA, LLCMounjaro, Trulicity | $286 | $113,03664 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $157 | $99,31974 claims |
| PfizerEliquis | $22 | $78,49358 claims |
| GSKTrelegy Ellipta | $140 | $37,12129 claims |
| Johnson & JohnsonXarelto | $33 | $24,23014 claims |
| AmgenProlia | $361 | $18,57511 claims |
| AstraZenecaBreztri Aerosphere | $564 | $12,64014 claims |
| AbbVieSynthroid | $45 | $1,62328 claims |
| Almatica Pharma LLCSertraline Hcl | $12 | $86573 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 578 hospitalist providers in Arizona.
Other hospitalist in Mesa
- Mashood SajjadMesa$3K
- Dheeraj BobbaMesa$2K
- Mohd JibreelMesa$2K
- Mark PostacchiniMesa$1K
- Izabela PostacchiniMesa$1K
- Paramvir SinghMesa$1K
- Jonathan JarvinaMesa$760
- Sachin MehtaScottsdale$10K
- Holly GeyerScottsdale$8K
- Aldine ChandlerTucson$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.